Drug intelligence / Profile preview

BR1018B-1

Development stage: Unknown
Lead developer: Boryung
Administration: Oral

Overview

BR1018B-1 is an investigational drug developed by Boryung Pharmaceutical Co., Ltd.. It is being evaluated in clinical trials, notably in a Phase 3 study where it is co-administered with BR1018C for the treatment of essential hypertension and primary hypercholesterolemia. Another study investigated the pharmacokinetic interaction and safety of BR1018-1 (likely referring to BR1018B-1) when administered alone and in combination with BR1018-2 in healthy adult subjects. The specific mechanism of action for BR1018B-1 has not been publicly disclosed.

Beyond the preview

Go deeper on BR1018B-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BR1018B-1.

Explore the full profile